Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis

Ueki, Yukitaka; Yamasaki, Satoshi; Kanamoto, Yasuhide; Kawazu, Tayo; Yano, Mototake; Matsumoto, Kazunari; Miyake, Seibei; Tominaga, Yoshinori; Iwamoto, U; Suemitsu, Junsuke; Matsuno, Yuichi; Sizume, Y; Takenaka, Yoshifumi; Eguchi, Katsumi

doi:10.1093/rheumatology/39.2.165

Cited by 54 publications

(85 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Leukocytapheresis (LCAP) is a therapeutic strategy for extracorporeal immunomodulation that has been used in several immunological disorders, such as rheumatoid arthritis. [4][5][6][7][8][9][10] In Japan, several open trials of LCAP for UC patients have accumulated encouraging results in bringing steroid-resistant patients into remission. [11][12][13][14][15][16] For example, the multicenter randomized controlled trial reported by Sawada et al 16 showed that the efficacy of LCAP therapy was significantly superior to that of high-dose steroid therapy (74% vs 38%; P ϭ 0.005).…”

Section: Introductionmentioning

confidence: 99%

Suppression of interleukin-1?- and tumor necrosis factor-�-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

et al. 2004

View full text Add to dashboard Cite

The relationship of parasitic liver disease to cholangiocarcinoma has long been debated, and it has been reported that cholangiocarcinoma is associated with opisthorchiasis viverrini. We report herein a rare case of cholangiocarcinoma associated with schistosomiasis japonica. A 76-year-old Japanese man with jaundice was diagnosed with cholangiocarcinoma. Radical resection was not done because of hepatic arterial and portal vein invasion. Biliary microwave tissue coagulation therapy was performed with placement of a metallic stent endoprosthesis. Twenty-two months after the treatment, however, the patient died from hematemesis. Autopsy findings revealed that there was no distant metastasis, even in the area of regional lymph node metastasis. The primary tumor in the hepatic hilar region had been replaced by necrotic debris resulting from the microwave therapy, and an expandable metallic stent was located in the center of the debris. Histological findings showed schistosome eggs, which were old and microcalcified, in veins in the colonic submucosa. Glisson's fibrosis around the cancer lesion suggested that schistosomiasis japonica and cholangiocarcinoma can occur together with severe chronic inflammation of the portal vein.

show abstract

Section: Introductionmentioning

confidence: 99%

Suppression of interleukin-1?- and tumor necrosis factor-�-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…LCAP was performed using a Cellsorba E column (Asahi Kasei Medical, Tokyo, Japan) installed in the extracorporeal circulation system (Plasauto LC; Asahi Kasei Medical) (6,7). For apheresis, venous access was secured via two large peripheral veins, and the blood was anticoagulated with nafamostat mesilate (Torii Pharmaceutical, Tokyo, Japan), a protease inhibitor that inhibits the activity of coagulation factors and platelet aggregation (6,7,(9)(10)(11)(12)(13)(14)(15). Heparin was not used, since its use has been associated with respiratory distress and palpitations (20).…”

Section: Methodsmentioning

confidence: 99%

“…In several trials, LCAP appeared to attenuate inflammation in patients with UC (8)(9)(10)(11) as well as patients with Crohn's disease (12), rheumatoid arthritis (13,14) and rapidly progressive glomerulonephritis (15), without provoking severe complications. Summarizing the results of previous clinical reports, Ortolano et al (8) concluded that 76% of 115 patients with IBD who were treated using LCAP entered remission, obviating the need for ongoing corticosteroid or cytoablative support.…”

Section: Introductionmentioning

confidence: 99%

Microarray analyses of peripheral whole blood cells from ulcerative colitis patients: Effects of leukocytapheresis

Kobayashi

Mitsuyama

Yamasaki

et al. 2013

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract.Complementary DNA microarray technology allows the simultaneous analysis of the expression of hundreds to thousands of genes. We applied this technique to clarify the molecular mechanisms underlying the therapeutic effects of leukocytapheresis (LCAP) therapy in patients with ulcerative colitis (UC). A 776-gene microarray analysis was performed using whole blood cells from six normal subjects and six patients with active UC who had undergone filtration LCAP. Widespread gene upregulation was observed in patients with UC, compared with normal subjects. After LCAP, genes with proinflammatory actions, such as CD97, CD74, human leukocyte antigen-DRβ1 and -DP light chain, were downregulated, while genes responsible for antimicrobial actions, such as neutrophil gelatinase-associated lipocalin, and acute phase reactions, such as haptoglobin α1S and α1-acid glycoprotein, were upregulated. In conclusion, we identified several genes expressed in the whole blood cells of UC patients as well as the transcriptional events following LCAP. Following LCAP, the gene profile shifted toward a pattern indicating disease improvement. These results suggest a basis for the molecular mechanisms leading to the therapeutic effects of LCAP and also indicate new therapeutic targets, providing important prognostic information.

show abstract

“…Cytapheresis has been shown recently to have clinical efficacy in various disease states, such as leukaemia, autoimmune disorders, rheumatoid arthritis, renal allograft rejection, and sickle-cell anaemia [1][2]. Various physicians have reported the efficacy of cytapheresis in inflammatory bowel disease such as ulcerative colitis and Crohn's disease [3][4][5][6][7][8]. The efficacy of LDL-apheresis in homozygous familial hypercholesterolemia and hyperlipidemia has been reported [9,10].…”

Section: Introductionmentioning

confidence: 99%

Affinity Binding Macroporous Monolithic Cryogel as a Matrix for Extracorporeal Apheresis Medical Devices

Akande

Mikhalovska²,

James

et al. 2015

IJBMR

View full text Add to dashboard Cite

Abstract:Cytapheresis is an extracorporeal separation technique widely used in medicine for elimination of specific classes of blood cells from circulating blood. It has been shown recently to have clinical efficacy in various disease states, such as leukaemia, autoimmune disorders, rheumatoid arthritis, renal allograft rejection and sickle-cell anaemia. The current study was undertaken to produce an affinity-binding column, based upon a macroporous monolithic cryogel with a structure of interconnected pores, with pore size and low flow resistance potentially suitable for use in cytapheresis. The affinity column was produced from poly (2-hydroxyethyl methacrylate) PHEMA cryogels synthesized by free radical polymerization at -12°C. This study involved assessing haemolytic potential, and functionalisation of polymer matrix with biological ligands. Haemolytic potential of poly (2-hydroxyethyl methacrylate) cryogel was established by measuring free haemoglobin after blood filtration through the column. The anti-human albumin (antibody) was chemically coupled to the epoxy derivatised monolithic cryogels and the binding efficiency of anti-human albumin (antibody) to the cryogel was determined. Our results show that approximately 100% of Red blood cells passed through the column with no evidence of haemolysis found in blood eluted. It was found that ~82% of human serum albumin was retained on the monolithic IgG anti-human albumin cryogel matrix. The obtained results suggest that poly (2-hydroxyethyl methacrylate) monolithic cryogel is a non-haemolytic material (haemocompatible matrix) capable of functionalisation with antibody and thus can be an appropriate matrix for use in extracorporeal apheresis system.

show abstract

Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis

Abstract: Our results suggest that filtration LCP to remove leucocytes from the peripheral blood exerts an immunomodulatory effect in patients with RA.

Cited by 54 publications

References 31 publications

Suppression of interleukin-1?- and tumor necrosis factor-�-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

Suppression of interleukin-1?- and tumor necrosis factor-�-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

Microarray analyses of peripheral whole blood cells from ulcerative colitis patients: Effects of leukocytapheresis

Affinity Binding Macroporous Monolithic Cryogel as a Matrix for Extracorporeal Apheresis Medical Devices

Contact Info

Product

Resources

About